Tags: Drug.
Resimmune is an experimental anti-T cell immunotoxin that is being investigated for treatment of T cell blood cancers such as cutaneous T cell lymphoma. It was developed by Doctors Neville Woo and Liu while at the National Institutes of Health (NIH) and is under exclusive license to Angimmune LLC. The therapy has potential applications for lymphomas and T cell driven autoimmune diseases including multiple sclerosis and graft-versus-host disease following stem cell or bone marrow transplant.